Kamal Adawi
CFO & TreasurerMr. Kamal Adawi, M.S., MBA, is Chief Financial Officer and Treasurer of Fate Therapeutics, Inc. from October 20, 2025 and was its Principal Financial Officer & Principal Accounting Officer from October 13, 2025. He served as Chief Financial Officer of Mindera Health since August 14, 2024. He had been Chief Financial Officer of Exagen Inc. since June 2017 until August 2024 and was its Corporate Secretary since September 2017. From 2014 to 2017, Mr. Adawi served as the Chief Financial Officer, Corporate Secretary and Treasurer at Pathway Genomics Corporation. Mr. Adawi served as Vice President of Finance of Pathway Genomics Corporation. Prior to joining Pathway Genomics, Mr. Adawi served as the Director of financial planning and analysis at Exagen Diagnostics, a commercial-stage diagnostics company focusing on testing for autoimmune rheumatic diseases. At Exagen, he established the finance department in San Diego to support its transition from a private company in New Mexico to an IPO-ready company in San Diego. He previously managed the finance departments for GenMark Dx and Digirad, both publicly traded diagnostic companies. He also served in various capacities in the finance and accounting departments at Becton, Dickinson and Co., a global medical technology company. His education includes three degrees in the field of business. Mr. Adawi earned a B.A. from Michigan State University with a major in finance, an MBA from Oakland University with a focus on management and a master’s degree in finance from San Diego State University.
Positions
- Company NameFate Therapeutics, Inc.Stock CodeFATEPositionCFO & TreasurerColleagues
- BVBahram ValamehrPresident, CEO & Director
- WHWilliam H. RastetterIndependent Chairman
- CRCindy R. TahlChief Legal & Compliance Officer and Corporate Secretary
- JFJessica FrancisSenior Vice President of Human Resources & Operations
- MHMartin HoskingHead of Research
- RSRobert S. EpsteinIndependent Director
- KJKarin JoossIndependent Director
- MCMatthew C. AbernethyIndependent Director
